Antiarrhythmic drug therapy for atrial fibrillation: Focus on atrial selectivity and safety

Cardiovascular and Hematological Agents in Medicinal Chemistry

Volumn 7, Issue 1, 2009, Pages 64-75

  Li, Danshi ^a   Sun, H ^a   Levesque, P ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

Antiarrhythmic drugs; Atrial fibrillation; Atrial selective agents; IKACh blocker; IKur blocker; Safety

Indexed keywords

2 [7 [3 (4 CYANOPHENOXY) 2 HYDROXYPROPYL] 9 OXA 3,7 DIAZABICYCLO[3.3.1]NON 3 YL]ETHYLCARBAMIC ACID TERT BUTYL ESTER; 2' (4 METHOXYPHENYLACETAMIDOMETHYL) N [2 (3 PYRIDYL)ETHYL] 2 BIPHENYLCARBOXAMIDE; ACETYLCHOLINE; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANTIARRHYTHMIC AGENT; AVE 1231; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOFETILIDE; FLECAINIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IBUTILIDE; ISQ 1; NIP 142; OMEGA 3 FATTY ACID; PLACEBO; PROPAFENONE; ROTIGAPTIDE; SOTALOL; TEDISAMIL; UNCLASSIFIED DRUG; VERNAKALANT; XEN D 0101;

ANTIARRHYTHMIC ACTIVITY; ARTICLE; BRADYCARDIA; CELL FUNCTION; CLINICAL TRIAL; COUGHING; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENCY; DRUG SAFETY; DRUG SELECTIVITY; DRUG STRUCTURE; DYSGEUSIA; GAP JUNCTION; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART MUSCLE POTENTIAL; HEART REPOLARIZATION; HEART RHYTHM; HEART VENTRICLE TACHYCARDIA; HUMAN; HYPOTENSION; IC 50; ISCHEMIC HEART DISEASE; NAUSEA; NONHUMAN; PARESTHESIA; POTASSIUM CURRENT; PRURITUS; QT PROLONGATION; RECOMMENDED DRUG DOSE; SIDE EFFECT; SNEEZING; DRUG DELIVERY SYSTEM; DRUG EFFECT; HEART ATRIUM; HEART ELECTROPHYSIOLOGY; PATHOPHYSIOLOGY; REVIEW; SINUS NODE;

ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; CARDIAC ELECTROPHYSIOLOGY; DRUG DELIVERY SYSTEMS; HEART ATRIA; HUMANS; SINOATRIAL NODE;

EID: 64149126280     PISSN: 18715257     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152509787047621     Document Type: Article

References (118)

1. Le Heusey, J.Y.; Paziaud, O.; Piot, O.; Said, M.A.; Copie, X. Lavergne, T. Cost of care distribution in atrial fibrillation patients: the COCAF study. Am. Heart J., 2004, 147, 121.
2. Benjamin, E.J.; Wolf, P.A.; D'Agostino, R.B.; Silbershatz, H.; Kannel, W.B.; Levy, D. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation, 1998, 98, 946.
3. Wolf, P.A.; Mitchell, J.B.; Baker, C.S.; Kannel, W.B.; D'Agostino, R.B. Impact of atrial fibrillation on mortality, stroke, and medical costs. Arch. Intern. Med., 1998, 158, 229.
4. Benjamin, E.J.; Levy, D.; Vaziri, S.M.; D'Agostino, R.B.; Belanger, A.J.; Wolf, P.A. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA, 1994, 271, 840.
5. Maisel, W.H.; Stevenson, L.W. Atrial fibrillation in heart failure: epidemiology, pathophysiology, and rationale for therapy. Am. J. Cardiol., 2003, 91, 2D.
6. Probst,P.; Goldschlager, N.; Selzer, A. Left atrial size and atrial fibrillation in mitral stenosis. Factors influencing their relationship. Circulation, 1973, 48, 1282.
7. Wyse, D.G.; Waldo, A.L.; DiMarco, J.P.; Domanski, M.J.; Rosenberg, Y.; Schron, E.B.; Kellen, J.C.; Green, H.L.; Mickel, M.C.; Dalquist, J.E.; Corley, S.D. A comparison of rate control and rhythm control in patients with atrial fibrillation. N. Engl. J. Med., 2002, 347, 1825.
8. Go, A.S.; Hylek, E.M.; Phillips, K.A.; Chang, Y.; Henault, L.E.; Selby, J.V.; Singer, D.E. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA, 2001, 285, 2370.
9. Feinberg, W.; Blackshear, J.; Laupacis, A.; Kronmal, R.; Hart, R. Prevalence, age distribution, and gender of patients with atrial fibrillation. Analysis and implications. Arch. Intern. Med., 1995, 155, 469.
10. Haïssaguerre, M.; Jaïs, P.; Shah, D.C.; Takahashi, A.; Hocini, M.; Quiniou, G.; Garrigue, S.; Le Mouroux, A.; Le Métayer, P.; Clémenty, J. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N. Engl. J. Med., 1998, 339, 659.
11. Oral, H.; Ozaydin, M.; Tada, H.; Chugh, A.; Scharf, C.; Hassan, S.; Lai, S.; Greenstein, R.; Pelosi, F.; Knight, B.P.; Strickberger, S.A.; Morady, F. Mechanistic significance of intermittent pulmonary vein tachycardia in patients with atrial fibrillation. J. Cardiovasc. Electrophysiol., 2002, 13, 645.
12. Pappone, C.; Rosanio, S.; Oreto, G.; Tocchi, M.; Gugliotta, F.; Vicedomini, G.; Salvati, A.; Dicandia, C.; Mazzone, P.; Santinelli, V.; Gulletta, S.; Chierchia, S. Circumferential radiofrequency ablation of pulmonary vein ostia: A new anatomic approach for curing atrial fibrillation. Circulation, 2000, 102, 2619. 13 Sundt, T.; Camillo, C.; Cox, J. The maze procedure for cure of atrial fibrillation. Cardiol. Clin., 1997, 15, 739.
13. Fuster, V.; Ryden, L.E.; Cannom, D.S.; Crijns, H.J.; Curtis, A.B.; Ellenbogen, K.A.; Halperin, J.L.; Le Heuzey, J.Y.; Kay, G.N.; Lowe, J.E.; Olsson, S.B.; Prystowsky, E.N.; Tamargo, J.L.; Wann, S.; Smith, S.C.; Jacobs, A.K.; Adams, C.D.; Anderson, J.L.; Antman, E.M.; Halperin, J.L.; Hunt, S.A.; Nishimura, R.; Ornato, J.P.; Page, R.L.; Riegel, B.; Priori, S.G.; Blanc, J.J.; Budaj, A.; Camm, A.J.; Dean, V. Deckers, J.W.; Despres, C.; Dickstein, K.; Lekakis, J.; McGregor, K.; Metra, M.; Morais, J.; Osterspey, A.; Tamargo, J.L.; Zamorano, J.L. ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines. Circulation, 2006, 114, e257.
14. Corley, S.D.; Epstein, A.E.; DiMarco, J.P.; Domanski, M.J.; Geller, N.; Greene, H.L.; Josephson, R.A.; Kellen, J.C.; Klein, R.C.; Krahn, A.D.; Mickel, M.; Mitchell, L.B.; Nelson, J.D.; Rosenberg, Y.; Schron, E.; Shemanski, L.; Waldo, A.L.; Wyse, D.G.; AFFIRM Investigators. Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study. Circulation, 2004, 109, 1509.
15. Nattel, S. New ideas about atrial fibrillation 50 years on. Nature, 2002, 415, 219.
16. Nattel, S.; Li, D. Ionic remodeling in the heart: pathophysiological significance and new therapeutic opportunities for atrial fibrillation. Circ. Res., 2000, 87, 440.
17. Nattel, S.; Li, D.; Yue, L. Basic mechanisms of atrial fibrillation - very new insights into very old ideas. Annu. Rev. Physiol., 2000, 62, 51.
18. Wijffels, M.C.; Kirchhof, C.J.; Dorland, R.; Allessie, M.A. Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats. Circulation, 1995, 92, 1954.
19. Van Wagoner, D.R.; Pond, A.L.; Lamorgese, M.; Rossie, S.S.; McCarthy, P.M.; Nerbonne, J.M. Atrial L-type Ca2+ currents and human atrial fibrillation. Circ. Res., 1999, 85, 428.
20. Yue, L.; Feng, J.; Gaspo, R.; Li, G.R.; Wang, Z.; Nattel, S. Ionic remodeling underlying action potential changes in a canine model of atrial fibrillation. Circ. Res., 1997, 81, 512.
21. Van Wagoner, D.R.; Pond, A.L.; McCarthy, P.M.; Trimmer, J.S.; Nerbonne, J.M. Outward K+ current densities and Kv1.5 expression are reduced in chronic human atrial fibrillation. Circ. Res. 1997, 80, 772.
22. Bosch, R.F.; Zeng, X.; Grammer, J.B.; Popovic, K.; Mewis, C.; Kühlkamp, V. Ionic mechanisms of electrical remodeling in human atrial fibrillation. Cardiovasc. Res., 1999, 44, 121.
23. Cha, T.J.; Ehrlich, J.R.; Chartier, D; Qi, X.Y.; Xiao, L.; Nattel, S. Kir3-based inward rectifier potassium current: potential role in atrial tachycardia remodeling effects on atrial repolarization and arrhythmias. Circulation, 2006, 113, 1730.
24. Ehrlich, J.R.; Cha, T.J.; Zhang, L.; Chartier, D.; Villeneuve, L.; Hébert, T.E.; Nattel, S. Characterization of a hyperpolarization-activated time-dependent potassium current in canine cardiomyocytes from pulmonary vein myocardial sleeves and left atrium. J. Physiol., 2004, 557, 583.
25. Dobrev, D.; Friedrich, A.; Voigt, N.; Jost, N.; Wettwer, E.; Christ, T.; Knaut, M.; Ravens, U. The G protein-gated potassium current I(K,ACh) is constitutively active in patients with chronic atrial fibrillation. Circulation, 2005, 112, 3697.
26. El-Armouche, A.; Boknik, P.; Eschenhagen, T.; Carrier, L.; Knaut, M.; Ravens, U.; Dobrev, D. Molecular determinants of altered Ca2+ handling in human chronic atrial fibrillation. Circulation, 2006, 114, 670.
27. Blaauw, Y.; Gogelein, H.; Tieleman, R.G.; Van, H.A.; Schotten, U.; Allessie, M.A. "Early" class III drugs for the treatment of atrial fibrillation: efficacy and atrial selectivity of AVE0118 in remodeled atria of the goat. Circulation, 2004, 110, 1717. 29 Duytschaever, M.; Blaauw, Y.; Allessie, M. Consequences of atrial electrical remodeling for the anti-arrhythmic action of class IC and class III drugs. Cardiovasc. Res., 2005, 67, 69.
28. Tse, H.F.; Lau, C.P. Electrophysiologic actions of dl-sotalol in patients with persistent atrial fibrillation. J. Am. Coll. Cardiol., 2002, 40, 2150.
29. Linz, D.K.; Afkham, F.; Itter, G.; Rutten, H.; Wirth, K.J. Effect of atrial electrical remodeling on the efficacy of antiarrhythmic drugs: comparison of amiodarone with I(Kr)- and I(to)/IKur-blockade in vivo. J. Cardiovasc. Electrophysiol., 2007, 18, 1313.
30. Bosch, R.F.; Nattel, S. Cellular electrophysiology of atrial fibrillation. Cardiovasc. Res., 2002, 54, 259.
31. Yue, L.; Melnyk, P.; Gaspo, R.; Wang, Z.; Nattel, S. Molecular mechanisms underlying ionic remodeling in a dog model of atrial fibrillation. Circ. Res., 1999, 84, 776.
32. Courtemanche, M.; Ramirez, R.J.; Nattel, S. Ionic targets for drug therapy and atrial fibrillation-induced electrical remodeling: insights from a mathematical model. Cardiovasc. Res., 1999, 42, 477.
33. Guerra, P.G.; Talajic, M.; Roy, D.; Dubuc, M.; Thibault, B.; Nattel, S. Is there a future for antiarrhythmic drug therapy? Drugs, 1998, 56, 767.
34. Torp-Pedersen, C.; Møller, M.; Bloch-Thomsen, P.E.; Køber, L.; Sandøe, E.; Egstrup, K.; Agner, E.; Carlsen, J.; Videbaek, J.; Marchant, B.; Camm, A.J. Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group. N. Engl. J. Med., 1999, 341, 857.
35. Kneller, J.; Kalifa, J.; Zou, R.; Zaitsev, A.V.; Warren, M.; Berenfeld, O.; Vigmond, E.J.; Leon, L.J.; Nattel, S.; Jalife, J. Mechanisms of atrial fibrillation termination by pure sodium channel blockade in an ionically-realistic mathematical model. Circ. Res., 2005, 96, e35.
36. Echt, D.S.; Liebson, P.R.; Mitchell, L.B.; Peters, R.W.; Obias-Manno, D.; Barker, A.H.; Arensberg, D.; Baker, A.; Friedman, L.; Greene, H.L. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N. Engl. J. Med., 1991, 324, 781.
37. Akhtar, M.; Breithardt, G.; Camm, A.J.; Coumel, P.; Janse, M.J.; Lazzara, R.; Myerburg, R.J.; Schwartz, P.J.; Waldo, A.L.; Wellens, H.J. CAST and beyond. Implications of the Cardiac Arrhythmia Suppression Trial. Task Force of the Working Group on Arrhythmias of the European Society of Cardiology. Circulation, 1990, 81, 1123.
38. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N. Engl. J. Med., 1989, 321, 406.
39. Wang, Z.; Fermini, B.; Nattel, S. Sustained depolarization-induced outward current in human atrial myocytes. Evidence for a novel delayed rectifier K+ current similar to Kv1.5 cloned channel currents. Circ. Res., 1993, 73, 1061.
40. Feng, J.; Wible, B.; Li, G.R.; Wang, Z.; Nattel, S. Antisense oligodeoxynucleotides directed against Kv1.5 mRNA specifically inhibit ultrarapid delayed rectifier K+ current in cultured adult human atrial myocytes. Circ. Res., 1997, 80, 572.
41. Peukert, S.; Brendel, J.; Pirard, B.; Strübing, C.; Kleemann, H.W.; Böhme, T.; Hemmerle, H. Pharmacophore-based search, synthesis, and biological evaluation of anthranilic amides as novel blockers of the Kv1.5 channel. Bioorg. Med. Chem. Lett., 2004, 14, 2823.
42. Matsuda, T.; Masumiya, H.; Tanaka, N.; Yamashita, T.; Tsuruzoe, N.; Tanaka, Y.; Tanaka, H.; Shigenoba, K. Inhibition by a novel anti-arrhythmic agent, NIP-142, of cloned human cardiac K+ channel Kv1.5 current. Life Sci., 2001, 68, 2017.
43. Gögelein, H.; Brendel, J.; Steinmeyer, K.; Strübing, C.; Picard, N.; Rampe, D.; Kopp, K.; Busch, A.E.; Bleich, M. Effects of the atrial antiarrhythmic drug AVE0118 on cardiac ion channels. Naunyn Schmiedebergs Arch. Pharmacol., 2004, 370, 183.
44. Wirth, K.J.; Paehler, T.; Rosenstein, B.; Knobloch, K.; Maier, T.; Frenzel, J.; Brendel, J.; Busch, A.E.; Bleich, M. Atrial effects of the novel K(+)-channel-blocker AVE0118 in anesthetized pigs. Cardiovasc. Res., 2003, 60, 298.
45. de Haan, S.;Greiser, M.; Harks, E.; Blaauw, Y.; van Hunnik, A.; Verheule, S.; Allessie, M.; Schotten, U. AVE0118, blocker of the transient outward current (I(to)) and ultrarapid delayed rectifier current (I(Kur)), fully restores atrial contractility after cardioversion of atrial fibrillation in the goat. Circulation, 2006, 114, 1234.
46. Wettwer, E.; Hála, O.; Christ, T.; Heubach, J.F.; Dobrev, D.; Knaut, M.; Varró, A.; Ravens, U. Role of IKur in controlling action potential shape and contractility in the human atrium: influence of chronic atrial fibrillation. Circulation, 2004, 110, 2299.
47. Blaauw, Y.; Schotten, U.; van Hunnik, A.; Neuberger, H.R.; Allessie, M.A. Cardioversion of persistent atrial fibrillation by a combination of atrial specific and non-specific class III drugs in the goat. Cardiovasc. Res., 2007, 75, 89.
48. Web site http://en.sanofi-aventis.com/rd/portfolio/ p_rd_portfolio_cardio.asp.
49. Wirth, K.J.; Brendel, J.; Steinmeyer, K.; Linz, D.K.;Gögelein, H. In vitro and in vivo effects of the atrial selective antiarrhythmic compound AVE1231. J. Cardiovasc. Pharmacol., 2007, 49, 197.
50. Rivard, L.; Shiroshita-Takeshita, A.; Maltais, C.; Ford, J.; Pinnock, R.; Madge, D.; Nattel, S. Electrophysiological and atrial antiarrhythmic effects of a novel IKur/Kv1.5 blocker in dogs. Heart Rhythm, 2(Suppl.), 2005, S180.
51. Kur/Kv1.5 blocker in dogs with atrial tachycardia remodeling. Heart Rhythm, 3(Suppl.), 2006, S183.
52. Website http://www.xention.com/PDFs/Phase1.pdf Website press release (2006).
53. Regan, C.P.; Stump, G.L.; Wallace, A.A.; Anderson, K.D.; McIntyre, C.J.; Liverton, N.J.; Lynch J.J. In vivo cardiac electrophysiologic and antiarrhythmic effects of an isoquinoline IKur blocker, ISQ-1, in rat, dog, and nonhuman primate. J. Cardiovasc. Pharmacol., 2007, 49, 236.
54. Lloyd, L.; Atwal, K.S.; Finlay, H.J.; Nyman, M.; Huynh, T.; Bhandaru, R.; Kover, A.; Schmidt, J.; Vaccaro, W.; Conder, M.; Jenkins-West, T.; Levesque, P. Benzopyran sulfonamides as KV1.5 potassium channel blockers. Bioorganic & Medicinal Chemistry Letters, 2007, 17, 3271.
55. Waldron, G.J.; Cole, W.C. Activation of vascular smooth muscle K+ channels by endothelium-derived relaxing factors. Clin. Exp. Pharmacol. Physiol., 1999, 26, 180.
56. Chung, S.; Saal, D.B.; Kaczmarek, L.K. Elimination of potassium channel expression by antisense oligonucleotides in a pituitary cell line. Proc. Natl. Acad. Sci., USA, 1995, 92, 5955.
57. Philipson, L.H.; Hice, R.E.; Schaefer, K.; LaMendola, J.; Bell, G.I.; Nelson, D.J.; Steiner, D.F. Sequence and functional expression in Xenopus oocytes of a human insulinoma and islet potassium channel. Proc. Natl Acad. Sci., USA, 1991, 88, 53.
58. Hashimoto, N.; Yamashita, T.; Tsuruzoe, N. Tertiapin, a selective IKACh blocker, terminates atrial fibrillation with selective atrial effective refractory period prolongation. Pharmacol. Res., 2006, 54, 136.
59. Matsuda, T.; Ito, M.; Ishimaru, S.; Tsuruoka, N.; Saito, T.; Iida-Tanaka, N. Hashimoto, N.; Yamashita, T.; Tsuruzoe, N.; Tanaka, H.; Shigenobu, K. Blockade by NIP-142, an antiarrhythmic agent, of carbachol-induced atrial action potential shortening and GIRK1/4 channel. J. Pharmacol. Sci., 2006, 101, 303.
60. Nagasawa, H.; Fujiki, A.; Fujikura, N.; Matsuda, T.; Yamashita, T.; Inoue, H. Effects of a novel class III antiarrhythmic agent, NIP-142, on canine atrial fibrillation and flutter. Circ. J., 2002, 66, 185.
61. Matsuda T, Masumiya H, Tanaka N, Yamashita T, Tsuruzoe N, Tanaka Y. Inhibition by a novel anti-arrhythmic agent, NIP-142, of cloned human cardiac K+ channel Kv1.5 current. Life Sci., 2001, 68, 2017-2024.
62. Seki, A.; Hagiwara, N.; Kasanuki, H. Effects of NIP-141 on K currents in human atrial myocytes. J. Cardiovasc. Pharmacol., 2002, 39, 29.
63. Tanaka, H.; Hashimoto N. A multiple ion channel blocker, NIP-142, for the treatment of atrial fibrillation. Cardiovasc Drug Rev, 2007, 25, 342.
64. Fedida, D. Vernakalant (RSD1235): a novel, atrial-selective antifibrillatory agent. Expert Opin. Investig. Drugs, 2007, 16, 519.
65. Roy, D.; Rowe, B.H.; Stiell, I.G.; Coutu, B.; Ip J.H.; Phaneuf, D.; Lee, J.; Vidaillet, H.; Dickinson, G.; Grant, S.; Ezrin, A.M.; Beatch, G.N.; for the CRAFT Investigators. A randomized, controlled trial of RSD1235, a novel anti-arrhythmic agent, in the treatment of recent onset atrial fibrillation. J. Am. Coll. Cardiol., 2004, 44, 2355.
66. Pratt, C.M; Navratil, J.; Nagy A. Oral vernakalant (RSD1235-SR) prevents recurrence of atrial fibrillation following cardioversion. Heart Rhythm, 2007, 4, S176.
67. Fedida, D.; Orth, P.M.; Chen, J.Y.; Lin, S.; Plouvier, B.; Jung, G.; Ezrin, A.M.; Beatch, G.N. The mechanism of atrial antiarrhythmic action of RSD1235. J. Cardiovasc. Electrophysiol., 2005, 16, 1227.
68. Orth PM, Hesketh JC, Mak CK, Yang Y, Lin S, Beatch GN. RSD1235 blocks late INa and suppresses early afterdepolarizations and torsades de pointes induced by class III agents. Cardiovasc. Res., 2006, 70, 486.
69. Dorian, P.; Pinter, A.; Mangat, I.; Korley, V.; Cvitkovic, S.; Beatch, G. The effect of vernakalant (RSD1235), an investigational antiarrhythmic agent, on atrial electrophysiology in humans. J. Cardiovasc. Pharmacol., 2007, 50, 35.
70. Carlsson, L.; Chartier, D.; Nattel, S. Characterization of the in vivo and in vitro electrophysiological effects of the novel antiarrhythmic agent AZD7009 in atrial and ventricular tissue of the dog. J. Cardiovasc. Pharmacol., 2006, 47, 123.
71. Persson, F.; Carlsson, L.; Duker, G.; Jacobson, I. Blocking characteristics of hERG, hNav1.5, and hKvLQT1/hminK after administration of the novel anti-arrhythmic compound AZD7009. J. Cardiovasc. Electrophysiol., 2005, 16, 329.
72. Goldstein, R.N.; Khrestian, C.; Carlsson, L.; Waldo, A.L. Azd7009: a new antiarrhythmic drug with predominant effects on the atria effectively terminates and prevents reinduction of atrial fibrillation and flutter in the sterile pericarditis model. J. Cardiovasc. Electrophysiol., 2004, 15, 1444.
73. Duker, G.; Björkman, J.A.; Linhardt, G.; Carlsson, L. AZD7009: a new antifibrillatory compound that markedly delays atrial refratoriness in the anesthetised dog. Heart Rhythm, 2004, 1, S159.
74. Crijns, H.C.; Van Gelder, I.C.; Walfridsson, H.; Kulakowski, P.; Rónaszéki, A.; Dedek, V.; Malm, A.; Almgren, O. Safe and effective conversion of persistent atrial fibrillation to sinus rhythm by intravenous AZD7009. Heart Rhythm, 2006, 3, 1321.
75. Geller, C.J.; Crijns, H.J.; Egstrup, K.; Kulakowski, P; Rosenqvist, M; Aunes-Jansson, M; Malm, A; Sager, P; Berggren, A; Berka, ZB; Berka, B. Pharmacological conversion with intravenous AZD7009 is as effective as DC cardioversion in patients with persistent atrial fibrillation lasting<30 days. Heart Rhythm, 2007, 4, S178.
76. Freestone, B.; Lip, G.Y. Tedisamil: a new novel antiarrhythmic. Expert. Opin. Investig.Drugs, 2004, 13, 151.
77. Dukes, I.; Cleemann, L.; Morad, M. Tedisamil blocks the transient and delayed rectifier K+ currents in mammalian cardiac and glial cells. J Pharmacol Exp Ther. 1990, 254, 560.
78. Wallace A.; Stupienski R.; Baskin E.; Appleby S.; Kothstein T.; Gehret J.; King S.; Remy D.; Lynch J. Cardiac electrophysiologic and antiarrhythmic actions of tedisamil. J Pharmacol Exp Ther. 1995, 273, 168.
79. Wettwer, E.; Himmel, H.M.; Amos, G.J.; Li, Q.; Metzger, F.; Ravens, U; Mechanism of block by tedisamil of transient outward current in human ventricular subepicardial myocytes. Br. J. Pharmacol., 1998, 125, 659.
80. Jost, N.; Virág L.; Hála O.; Varro, A.; Thormählen, D.; Papp, J. Effect of the antifibrillatory compound tedisamil (KC-8857) on transmembrane currents in mammalian ventricular myocytes. Curr Med Chem. 2004, 11, 3219.
81. Hohnloser S.H.; Dorian, P.; Straub, M.; Beckmann, K.; Kowey, P. Safety and efficacy of intravenously administered tedisamil for rapid conversion of recent-onset atrial fibrillation or atrial flutter. J. Am. Coll. Cardiol., 2004, 44, 99.
82. FDA Website: http://www.fda.gov/ohrms/dockets/default.htm.
83. Kanno, S.; Saffitz, J.E. The role of myocardial gap junctions in electrical conduction and arrhythmogenesis. Cardiovasc. Pathol., 2001, 10, 169.
84. Peters, N.S.; Coromilas, J.; Severs, N.J.; Wit, A.L. Disturbed connexin43 gap junction distribution correlates with the location of reentrant circuits in the epicardial border zone of healing canine infarcts that cause ventricular tachycardia. Circulation, 1997, 95, 988.
85. Wetzel U, Boldt A, Lauschke J.; Weigl, J.; Schirdewahn, P.; Dorszewski, A.; Doll, N.; Hindricks, G.; Dhein, S.; Kottkamp, H. Expression of connexins 40 and 43 in human left atrium in atrial fibrillation of different aetiologies. Heart, 2005, 91, 166.
86. van der Velden, H.M.; Ausma, J.; Rook, M.B.; Hellemons, A.J.; van Veen, T.A.; Allessie, M.A.; Jongsma, H.J. Gap junctional remodeling in relation to stabilization of atrial fibrillation in the goat. Cardiovasc. Res., 2000, 46, 476.
87. Nao, T.; Ohkusa, T.; Hisamatsu, Y.; Inoue, N.; Matsumoto, T.; Yamada, J.; Shimizu, A.; Yoshiga, Y.; Yamagata, T.; Kobayashi, S.; Yano, M.; Hamano, K.; Matsuzaki, M. Comparison of expression of connexin in right atrial myocardium in patients with chronic atrial fibrillation versus those in sinus rhythm. Am. J. Cardiol., 2003, 91, 678.
88. Kanagaratnam, P.; Cherian, A.; Stanbridge, R.D.; Glenville, B.; Severs, N.J.; Peters, N.S. Relationship between connexins and atrial activation during human atrial fibrillation. J. Cardiovasc. Electrophysiol., 2004, 15, 206.
89. Gollob, M.H.; Jones, D.L.; Krahn, A.D.; Danis, L.; Gong, X.Q.; Shao, Q.; Liu, X.; Veinot, J.P.; Tang, A.S.; Stewart, A.F.; Tesson, F.; Klein, G.J.; Yee, R.; Skanes, A.C.; Guiraudon, G.M. Ebihara, L.; Bai, D. Somatic mutations in the connexin 40 gene (GJA5) in atrial fibrillation. N. Engl. J. Med., 2006, 354, 2677.
90. Juang, J.M.; Chern, Y.R.; Tsai, C.T.; Chiang, F.T.; Lin, J.L.; Hwang, J.J.; Hsu, K.L.; Tseng, C.D.; Tseng, Y.Z.; Lai, L.P. The association of human connexin 40 genetic polymorphisms with atrial fibrillation. Int. J. Cardiol., 2007, 116, 107.
91. Kjølbye, A.L.; Haugan, K.; Hennan, J.K.; Petersen, J.S. Pharmacological modulation of gap junction function with the novel compound rotigaptide: a promising new principle for prevention of arrhythmias. Basic Clin. Pharmacol. Toxicol., 2007, 101, 215.
92. Guerra, J.M.; Everett, T.H.; Lee, K.W.; Wilson, E.; Olgin, J.E. Effects of the gap junction modifier rotigaptide (ZP123) on atrial conduction and vulnerability to atrial fibrillation. Circulation, 2006, 114, 110.
93. Shiroshita-Takeshita, A.; Sakabe, M.; Haugan, K.; Hennan, J.K.; Nattel, S. Model-dependent effects of the gap junction conduction-enhancing antiarrhythmic peptide rotigaptide (ZP123) on experimental atrial fibrillation in dogs. Circulation, 2007, 115, 310.
94. Web site: www.zealandpharma.com/Product-Pipeline/Rotigaptide
95. Sanders, P.; Morton, J.B.; Davidson, N.C.; Spence, S.J.; Vohra, J.K.; Sparks, P.B.; Kalman, J.M. Electrical remodeling of the atria in congestive heart failure: electrophysiological and electro-anatomic mapping in humans. Circulation, 2003, 108, 1461.
96. Li, D.; Shinagawa, K.; Pang, L.; Leung, T.K.; Cardin, S.; Wang, Z.; Nattel, S. Effects of angiotensin-converting enzyme inhibition on the development of the atrial fibrillation substrate in dogs with ventricular tachypacing-induced congestive heart failure. Circulation, 2001, 104, 2608.
97. Korantzopoulos, P.; Kolettis, T.M.; Galaris, D.; Goudevenos, J.A. The role of oxidative stress in the pathogenesis and perpetuation of atrial fibrillation. Int. J. Cardiol., 2007, 115, 135.
98. Ehrlich, J.; Hohnloser, S.; Nattel, S. Role of angiotensin system and effects of its inhibition in atrial fibrillation: clinical and experimental evidence. Eur. Heart J., 2006, 27, 512.
99. Goette, A.; Staack, T.; Röcken, C.; Arndt, M.; Geller, J.C.; Huth, C.; Ansorge, S.; Klein, H.U.; Lendeckel, U. Increased expression of extracellular signal-regulated kinase and angiotensin-converting enzyme in human atria during atrial fibrillation. J. Am. Coll. Cardiol., 2000, 35, 1669.
100. Pederson, O.D.; Bagger, H.; Kober, L.; Torp-Pedersen, C. Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction. Circulation, 1999, 100, 376.
101. Anand, K.; Mooss, A.N.; Hee, T.T.; Mohiuddin, S.M. Meta-analysis: inhibition of renin-angiotensin system prevents new-onset atrial fibrillation. Am. Heart J., 2006, 151, 217.
102. Ueng, K.C.; Tsai, T.P.; Yu, W.C.; Tsai, C.F.; Lin, M.C.; Chan, K.C.; Chen, C.Y.; Wu, D.J.; Lin, C.S.; Chen, S.A. Use of enalapril to facilitate sinus rhythm maintenance after external cardioversion of long-standing persistent atrial fibrillation. Results of a prospective and controlled study. Eur. Heart J., 2003, 24, 2090.
103. Murray, K.T.; Rottman, J.N.; Arbogast, P.G.; Shemanski, L.; Primm, R.K.; Campbell, W.B.; Solomon, A.J.; Olgin, J.E.; Wilson, M.J.; Dimarco, J.P.; Beckman, K.J.; Dennish, G.; Naccarelli, G.V.; Ray, W.A.; the AFFIRM Investigators. Inhibition of angiotensin II signaling and recurrence of atrial fibrillation in AFFIRM. Heart Rhythm, 2004, 1, 669.
104. Madrid, A.H.; Bueno, M.G.; Rebollo, J.M.; Marín, I.; Peña, G.; Bernal, E.; Rodriguez, A.; Cano, L.; Cano, J.M.; Cabeza, P.; Moro, C. Use of irbesartan to maintain sinus rhythm in patients with longlasting persistent atrial fibrillation: a prospective and randomized study. Circulation, 2002, 106, 331.
105. Wachtell, K.; Lehto, M.; Gerdts, E.; Olsen, M.H.; Hornestam, B.; Dahlöf, B.; Ibsen, H.; Julius, S.; Kjeldsen, S.E.; Lindholm, L.H.; Nieminen, M.S.; Devereux, R.B. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. J. Am. Coll. Cardiol., 2005, 45, 712.
106. Darbar, D.; Motsinger, A.A.; Ritchie, M.D.; Gainer, J.V.; Roden, D.M. Polymorphism modulates symptomatic response to antiarrhythmic drug therapy in patients with lone atrial fibrillation. Heart Rhythm. 2007, 4, 743.
107. Milliez, P.; Girerd, X.; Plouin, P.F.; Blacher, J.; Safar, M.E.; Mourad, J.J. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J. Am. Coll. Cardiol., 2005, 45, 1243.
108. Ram, R.; Van Wagoner D.R. Aldosterone antagonism as an antiarrhythmic approach for atrial arrhythmias in heart failure. J. Cardiovasc. Electrophysiol., 2006, 17, 542.
109. Shroff, S.C.; Ryu, K.; Martovitz, N.L.; Hoit, B.D.; Stambler, B.S. Selective aldosterone blockade suppresses atrial tachyarrhythmias in heart failure. J. Cardiovasc. Electrophysiol., 2006, 17, 534.
110. Young-Xu, Y.; Jabbour, S.; Goldberg, R.; Blatt, C.M.; Graboys, T.; Bilchik, B.; Ravid, S. Usefulness of statin drugs in protecting against atrial fibrillation in patients with coronary artery disease. Am. J. Cardiol., 2003, 92, 1379.
111. Ozaydin, M.; Varol, E.; Aslan, S.M.; Kucuktepe, Z.; Dogan, A.; Ozturk, M.; Altinbas, A. Effect of atorvastatin on the recurrence rates of atrial fibrillation after electrical cardioversion. Am. J. Cardiol., 2006, 97, 1490.
112. Siu, C.W.; Lau, C.P.; Tse, H.F. Prevention of atrial fibrillation recurrence by statin therapy in patients with lone atrial fibrillation after successful cardioversion. Am. J. Cardiol., 2003, 92, 1343.
113. Patti, G.; Chello, M.; Candura, D.; Pasceri, V.; D'Ambrosio, A.; Covino, E.; Di Sciascio, G. Randomized trial of atorvastatin for reduction of postoperative atrial fibrillation in patients undergoing cardiac surgery: results of the ARMYDA-3 (Atorvastatin for Reduction of MYocardial Dysrhythmia After cardiac surgery) study. Circulation, 2006, 114, 1455.
114. Marin, F.; Pascual, DA.; Roldan, V.; Arribas, J.M.; Ahumada, M.; Tornel, P.L.; Oliver, C.; Gómez-Plana, J.; Lip, G.Y.; Valdés, M. Statins and postoperative risk of atrial fibrillation following coronary artery bypass grafting. Am. J. Cardiol., 2006, 97, 55.
115. Korantzopoulos, P.; Kolettis, T.M.; Galaris, D.; Goudevenos, J.A. The role of oxidative stress in the pathogenesis and perpetuation of atrial fibrillation. Int. J. Cardiol., 2007, 115, 135.
116. Mozaffarian, D.; Psaty, B.M.; Rimm, E.B.; Lemaitre, R.N.; Burke, G.L.; Lyles, M.F.; Lefkowitz, D.; Siscovick, D.S. Fish intake and risk of incident atrial fibrillation. Circulation, 2004, 110, 368.
117. Calò, L.; Bianconi, L.; Colivicchi, F.; Lamberti, F.; Loricchio, M.L.; de Ruvo, E.; Meo, A.; Pandozi, C.; Staibano, M.; Santini, M. N-3 Fatty acids for the prevention of atrial fibrillation after coronary artery bypass surgery: a randomized, controlled trial. J. Am. Coll. Cardiol., 2005, 45, 1723.
118. Brouwer, I.A.; Heeringa, J.; Geleijnse, J.M.; Zock, P.L.; Witteman, J.C. Intake of very long-chain n-3 fatty acids from fish and incidence of atrial fibrillation. The Rotterdam Study. Am. Heart J., 2006, 151, 857.